Intrauterine adhesions Medical Services in China

Intrauterine adhesions (IUA), also known as Asherman’s syndrome, are fibrous bands of scar tissue that form within the uterine cavity, leading to partial or complete obliteration of the endometrial space. These adhesions result from trauma-induced damage to the basal layer of the endometrium—most commonly following dilation and curettage (D&C) after miscarriage or postpartum hemorrhage, but also after uterine surgery (e.g., myomectomy, cesarean section), infection (chronic endometritis), or radiation therapy. Pathogenesis centers on defective re-epithelialization: injury disrupts the delicate balance between tissue repair and fibrosis, triggering excessive collagen deposition by activated fibroblasts and myofibroblasts, often exacerbated by impaired angiogenesis and reduced stem cell recruitment in the damaged endometrium. Epidemiologically, IUA affects an estimated 1.5–22% of women undergoing D&C for pregnancy-related complications, with higher prevalence (up to 30%) among those with recurrent pregnancy loss or repeated uterine instrumentation. Risk factors include multiple D&Cs, surgical termination in the second trimester, history of pelvic tuberculosis (especially in endemic regions), severe intrauterine infection, and possibly genetic predisposition to aberrant wound healing. Clinically, symptoms range from amenorrhea or hypomenorrhea (most common), cyclic pelvic pain (due to trapped menstrual blood), infertility, and recurrent pregnancy loss—though some cases remain asymptomatic until fertility evaluation. The condition profoundly impacts quality of life: women often experience emotional distress, anxiety about fertility, sexual dysfunction due to pain or fear of conception failure, and diminished self-perception related to reproductive identity. Untreated IUA carries high risks of obstetric complications—including placenta accreta spectrum disorders, preterm birth, and intrauterine growth restriction—if pregnancy occurs. Early diagnosis via saline infusion sonohysterography (SIS) or hysteroscopy is critical; hysteroscopy remains the gold standard for both diagnosis and therapeutic intervention. Management aims not only to restore uterine anatomy but also to regenerate functional endometrium—requiring a multimodal approach combining mechanical adhesiolysis, intrauterine barrier placement (e.g., hyaluronic acid gel or balloon catheter), hormonal support (estrogen-progesterone regimens), and sometimes adjunctive therapies like platelet-rich plasma (PRP) or stem cell applications in refractory cases. Long-term follow-up with repeat hysteroscopy is essential to assess endometrial recovery and prevent recurrence, which occurs in 20–62% of moderate-to-severe cases without optimal adjuvant therapy.

Intrauterine adhesions (IUAs), also known as Asherman syndrome, represent a pathological condition characterized by the formation of fibrous bands—ranging from thin, avascular strands to dense, vascularized scar tissue—that bridge opposing walls of the uterine cavity. These adhesions result from damage to the basal layer of the endometrium and underlying myometrium, disrupting normal regenerative capacity and triggering aberrant fibroblastic proliferation and collagen deposition. The most common cause is iatrogenic trauma, particularly following dilation and curettage (D&C) procedures performed for pregnancy-related complications—including missed or incomplete miscarriage, postpartum hemorrhage, or elective termination—accounting for approximately 90% of documented cases. The risk escalates significantly when D&C is performed within the first 4 weeks postpartum or during active infection, due to heightened endometrial vulnerability and impaired wound healing. Other surgical insults include hysteroscopic resection of submucosal fibroids or polyps, endometrial ablation (especially thermal modalities), cesarean delivery with inadvertent uterine cavity entry, and myomectomy involving the endometrial surface. Infectious etiologies, though less frequent in high-resource settings, remain clinically relevant: chronic endometritis—often secondary to Mycobacterium tuberculosis, Chlamydia trachomatis, or mixed aerobic/anaerobic organisms—induces persistent inflammation, glandular atrophy, and stromal fibrosis. Tuberculous endometritis, in particular, is associated with severe, diffuse adhesion formation and near-total cavity obliteration, especially in endemic regions.

Triggers for adhesion development involve both mechanical and biological mechanisms. Mechanical disruption of the endometrium exposes the highly thrombogenic basal layer, initiating coagulation cascade activation and fibrin deposition. In the absence of timely epithelialization—typically occurring within 7–10 days—fibrin scaffolds become infiltrated by fibroblasts and myofibroblasts, which deposit excessive type I and III collagen. Concurrently, dysregulated expression of transforming growth factor-beta (TGF-β), connective tissue growth factor (CTGF), and plasminogen activator inhibitor-1 (PAI-1) suppresses fibrinolysis and promotes extracellular matrix accumulation. Hormonal milieu also modulates risk: hypoestrogenic states—such as those induced by GnRH agonists preoperatively or occurring postpartum—impair endometrial proliferation and delay re-epithelialization, thereby extending the window for fibrotic organization.

Established risk factors include procedural variables (e.g., repeated D&Cs, use of sharp rather than suction curettage, operator inexperience), clinical context (postpartum or postabortal status, presence of intrauterine infection), and patient-specific characteristics. Advanced maternal age (>35 years) correlates with diminished endometrial stem cell reserve and reduced angiogenic potential. Prior history of IUAs markedly increases recurrence risk after adhesiolysis, with severity (American Fertility Society classification grade) strongly predictive of reproductive outcomes. Obesity (BMI ≥30 kg/m²) is associated with chronic low-grade inflammation, elevated leptin and TGF-β levels, and impaired tissue repair. Smoking induces vasoconstriction, oxidative stress, and downregulation of estrogen receptor alpha, further compromising endometrial perfusion and regeneration.

No monogenic inheritance pattern has been identified for IUAs; however, emerging evidence suggests polygenic susceptibility. Polymorphisms in genes regulating fibrinolysis (e.g., PAI-1 4G/5G), extracellular matrix remodeling (MMP-2, MMP-9, TIMP-1), and inflammatory response (IL-6, TNF-α promoters) may influence individual propensity to fibrosis following endometrial injury. Epigenetic modifications—including DNA methylation of WNT pathway inhibitors and histone acetylation changes in fibrotic gene promoters—have been observed in endometrial biopsies from affected patients, suggesting environmentally modulated transcriptional dysregulation.

Environmental factors encompass geographic, socioeconomic, and healthcare-system determinants. In low- and middle-income countries, limited access to safe abortion services leads to higher rates of septic abortion and subsequent endometritis-driven adhesions. Poor sanitation, delayed presentation, and antibiotic shortages exacerbate infectious risks. Occupational exposures are not directly implicated, but chronic psychosocial stress—via hypothalamic-pituitary-adrenal axis activation and cortisol-mediated suppression of endometrial integrins and growth factors—may indirectly impair mucosal repair. Additionally, environmental endocrine disruptors (e.g., bisphenol A, phthalates) have demonstrated anti-estrogenic effects in vitro and may attenuate endometrial responsiveness to estradiol, potentially contributing to suboptimal post-injury recovery.

Intrauterine adhesions (IUAs), also known as Asherman syndrome, represent a pathological condition characterized by the formation of fibrous bands—ranging from thin, avascular strands to dense, vascularized scar tissue—within the uterine cavity. These adhesions result from endometrial basal layer injury, most commonly following uterine instrumentation such as dilation and curettage (D&C), particularly after miscarriage or postpartum hemorrhage, but also after cesarean delivery, myomectomy, hysteroscopic resection, or intrauterine infection (e.g., genital tuberculosis or chronic endometritis). The severity of IUAs is classified using standardized systems (e.g., the European Society of Gynaecological Endoscopy [ESGE] or American Fertility Society [AFS] scoring), which consider the extent, location, and density of adhesions, as well as the degree of cavity obliteration.

Early symptoms are often subtle or entirely absent, especially in mild cases. Many patients remain asymptomatic until reproductive goals are pursued. However, early clinical clues may include a progressive reduction in menstrual flow (hypomenorrhea) following a triggering event—most notably within one to three cycles after D&C. Some women report complete cessation of menses (amenorrhea) as the first noticeable sign, though this typically reflects more extensive involvement. Others describe cyclical pelvic pain (dysmenorrhea) without bleeding—a phenomenon termed 'cryptomenorrhea'—suggesting functional endometrium remains active but outflow is obstructed by adhesions. Early-stage IUAs may also manifest as unexplained infertility or recurrent pregnancy loss prior to formal diagnosis, prompting referral to reproductive medicine specialists.

Typical symptoms reflect the anatomical and functional consequences of intrauterine scarring. Oligomenorrhea (infrequent, scant menses) and amenorrhea are hallmark presentations, occurring in up to 40% and 25% of moderate-to-severe cases, respectively. Menstrual abnormalities correlate strongly with the extent of basal endometrial destruction: when the regenerative stratum basalis is compromised, endometrial renewal fails, leading to atrophy and cavity narrowing. Patients frequently report secondary infertility—the inability to conceive after previously achieving pregnancy—due to mechanical obstruction of sperm transport, impaired embryo implantation, or disrupted endometrial receptivity. Recurrent spontaneous abortion (RSA), particularly in the first trimester, is another common presentation, attributable to inadequate decidualization, placental insufficiency, or abnormal placentation (e.g., placenta accreta spectrum) in scarred, poorly vascularized endometrium. Chronic pelvic pain, while less specific, may arise from cyclic distension of trapped secretions behind adhesions or associated myometrial hypercontractility.

Accompanying symptoms often point to underlying etiologies or comorbid conditions. Women with post-infectious IUAs (e.g., tuberculosis or chronic endometritis) may exhibit low-grade fevers, fatigue, or systemic inflammatory markers. Those with concomitant cervical stenosis or synechiae extending into the isthmus may experience hematometra, presenting as acute lower abdominal pain and palpable uterine enlargement. Hormonal evaluation typically reveals normal gonadotropin and estradiol levels, distinguishing IUAs from hypothalamic-pituitary-ovarian axis disorders; however, prolonged anovulation secondary to chronic stress or weight loss may coexist. Psychological distress—including anxiety, depression, and grief—is highly prevalent due to fertility impairment and repeated treatment failures, warranting integrated psychosocial support.

Complications extend beyond reproductive morbidity. Severe adhesions predispose to obstetric emergencies: placenta previa, placenta accreta/increta/percreta, vasa previa, and preterm birth occur at significantly elevated rates. Intrapartum complications include uterine rupture, postpartum hemorrhage, and failed labor induction due to poor myometrial contractility in scarred segments. Endometrial atrophy increases susceptibility to endometrial hyperplasia or carcinoma in women receiving unopposed estrogen therapy without adequate endometrial surveillance. Rarely, hydrometra or pyometra develops if adhesions cause complete outflow obstruction with secondary infection. Long-term sequelae include premature ovarian insufficiency in cases where surgical trauma extends to the ovarian blood supply during aggressive hysteroscopic dissection, though this is uncommon.

Diagnosis relies on a high index of clinical suspicion combined with imaging and direct visualization. Transvaginal ultrasound (TVUS) serves as initial screening: findings suggestive of IUAs include a thin (<7 mm) or irregular endometrial stripe, hypoechoic intrauterine bands, or absence of normal triple-line pattern during proliferative phase. Three-dimensional (3D) saline infusion sonohysterography (SIS) enhances sensitivity by distending the cavity and delineating adhesion morphology, location, and attachment points. However, hysteroscopy remains the gold standard diagnostic and therapeutic modality. Diagnostic hysteroscopy permits real-time assessment of adhesion type (filmy vs. dense), vascularity, and extent, enabling immediate classification and guiding management decisions. Magnetic resonance imaging (MRI) is reserved for complex cases—such as suspected tuberculous endometritis or extensive myometrial involvement—to evaluate extracavitary pathology and differentiate from müllerian anomalies.

Differential diagnosis is critical to avoid misattribution. Hypothalamic amenorrhea presents with low FSH/LH and estradiol, often associated with stress, exercise, or weight loss—unlike IUAs, which feature normal hormonal profiles. Premature ovarian insufficiency (POI) shows elevated FSH (>25 IU/L) and low AMH, whereas IUAs preserve ovarian reserve. Mullerian anomalies (e.g., unicornuate or septate uterus) may mimic cavity distortion on imaging but lack post-procedural onset and demonstrate characteristic external uterine contours on MRI. Endometrial polyps or submucosal fibroids can cause similar menstrual disturbances but appear as discrete, mobile, echogenic masses distinct from linear, fixed adhesions. Chronic endometritis—often coexisting with IUAs—may present with similar symptoms but is diagnosed via endometrial biopsy showing plasma cell infiltration (CD138+), not structural adhesions. Finally, cervical stenosis must be excluded via gentle sounding before attributing amenorrhea to intrauterine pathology, as it produces identical outflow obstruction without intracavitary scarring.

Intrauterine adhesions (IUAs), also known as Asherman syndrome, represent a pathological condition characterized by the formation of fibrous bands—ranging from thin, avascular strands to dense, vascularized scar tissue—within the uterine cavity. These adhesions typically result from trauma to the endometrial basal layer, most commonly following dilation and curettage (D&C) for miscarriage or postpartum hemorrhage, but may also arise after cesarean delivery, myomectomy, uterine infection (e.g., genital tuberculosis), or chronic endometritis. Clinical manifestations include amenorrhea or hypomenorrhea, recurrent pregnancy loss, implantation failure in assisted reproductive technology (ART), and infertility. Diagnosis relies on hysteroscopy—the gold standard—as saline infusion sonography (SIS) and transvaginal ultrasound serve only as adjunctive screening tools. Treatment is stratified according to adhesion severity (classified using the European Society of Gynaecological Endoscopy [ESGE] or American Fertility Society [AFS] scoring systems), symptom burden, and reproductive goals.

Conservative management is reserved for asymptomatic patients with mild, non-obstructive adhesions and no fertility concerns—or for those who decline or are not candidates for surgery. It emphasizes surveillance and hormonal modulation to support endometrial regeneration. Patients undergo serial clinical evaluation every 3–6 months, including menstrual history assessment and pelvic ultrasound to monitor endometrial thickness and pattern. While no randomized trials support routine conservative therapy alone for moderate-to-severe IUAs, low-dose estrogen-progestin regimens (e.g., estradiol valerate 2 mg daily × 21 days plus medroxyprogesterone acetate 10 mg daily × 10 days) may be trialed for 2–3 cycles in select cases with minimal synechiae and preserved basal endometrium. However, evidence for efficacy remains limited, and conservative approaches do not address mechanical obstruction or restore cavity architecture.

Pharmacologic interventions serve primarily as adjuncts—not standalone therapies. Estrogen therapy (typically oral or transdermal estradiol 4–6 mg/day for 2–4 weeks postoperatively) aims to stimulate endometrial proliferation and inhibit fibroblast collagen synthesis. A meta-analysis of 12 RCTs demonstrated that postoperative estrogen significantly improves endometrial thickness (mean difference +2.1 mm; 95% CI 1.4–2.8) and reduces adhesion recurrence (RR 0.57; 95% CI 0.41–0.79). Antibiotics (e.g., doxycycline 100 mg BID × 7 days) are routinely administered perioperatively to mitigate infection-related fibrosis. Emerging agents under investigation include intrauterine hyaluronic acid gels (e.g., Hyalobarrier®), which act as physical barriers to re-adhesion formation; studies report ~30% relative reduction in recurrence versus placebo when applied immediately after adhesiolysis. Pentoxifylline and aspirin have been explored for antifibrotic and antiplatelet effects, respectively, though robust clinical data are lacking. Notably, gonadotropin-releasing hormone agonists (GnRHa) are contraindicated preoperatively, as they induce hypoestrogenic atrophy that impairs endometrial healing and increases intraoperative bleeding risk.

Surgical treatment—hysteroscopic adhesiolysis—is the cornerstone of definitive management. Performed under direct visualization using either rigid or flexible hysteroscopes, it involves meticulous lysis of adhesions using microscissors, blunt dissection, or low-power monopolar/bipolar electrodes. Cold instrumentation is preferred for filmy adhesions to minimize thermal injury; electrocautery is reserved for dense, vascularized bands with strict attention to depth control. The procedure requires expertise in recognizing the endometrial-myometrial junction to avoid perforation or excessive myometrial resection. In severe cases (ESGE grade III–IV), staged surgery may be indicated: initial lysis followed by estrogen priming and repeat hysteroscopy in 4–6 weeks to address residual or recurrent adhesions. Intraoperative ultrasound guidance enhances safety during deep dissection. Postoperative intrauterine device (IUD) placement is discouraged due to infection and embedment risks; instead, balloon catheters (e.g., Foley 10–12 Fr) inflated with 2–3 mL saline are placed for 5–7 days to maintain cavity separation, with proven superiority over IUDs in recurrence prevention (OR 0.32; 95% CI 0.18–0.57).

China offers distinct advantages in IUA management, particularly within specialized Reproductive Medicine Departments. First, high-volume centers—such as Peking University Third Hospital, Shanghai Jiao Tong University Affiliated International Peace Maternity and Child Health Hospital, and Nanjing Drum Tower Hospital—perform >500 hysteroscopic adhesiolyses annually, fostering unparalleled operator proficiency and standardized protocols aligned with ESGE guidelines. Second, China leads in translational innovation: domestically developed hysteroscopic platforms (e.g., Wisonic HD-3000) integrate real-time AI-assisted tissue differentiation, improving identification of residual adhesions. Third, integrated care models combine reproductive endocrinology, reproductive immunology, and chronic endometritis diagnostics (via CD138 immunohistochemistry and PCR-based endometrial microbiome profiling), enabling personalized postoperative strategies. Fourth, cost-effectiveness is notable: comprehensive surgical management—including hysteroscopy, histopathology, and 3-month follow-up—averages USD $1,800–$2,500, substantially lower than comparable care in Western Europe or North America, without compromising outcomes. Finally, national registries (e.g., China IUA Registry) facilitate longitudinal outcome tracking, informing evidence-based refinements in adjuvant therapy selection.

Post-treatment recovery necessitates structured, multidisciplinary follow-up. Patients receive oral estradiol (4 mg/day) for 2 weeks, then combined estrogen-progestin for an additional 2 weeks, followed by a withdrawal bleed. A diagnostic hysteroscopy is scheduled at 6–8 weeks to assess cavity patency and endometrial quality; if adhesions recur, early reintervention yields superior outcomes. Lifestyle counseling includes avoidance of vaginal intercourse and tampon use for 4 weeks, smoking cessation (nicotine impairs angiogenesis), and nutritional optimization (adequate vitamin E, omega-3 fatty acids, and iron to support endometrial repair). For patients pursuing conception, ovulation induction or IVF is deferred until two consecutive normal menstrual cycles and confirmed cavity integrity. Pregnancy rates after successful adhesiolysis range from 45% (mild) to 25% (severe); live birth rates correlate strongly with postoperative endometrial thickness ≥7 mm and absence of central adhesions. Long-term monitoring includes annual transvaginal ultrasound and endometrial biopsy in women with prior severe IUAs to screen for atrophy or hyperplasia. Psychological support is integral, given the high prevalence of anxiety and depression linked to infertility and recurrent loss. Ultimately, optimal IUA management demands individualized, stage-specific intervention, rigorous surgical technique, evidence-based adjuvant therapy, and sustained reproductive health surveillance.